News
In February 2025 Harbour BioMed announced that the IND application for HBM9378 (SKB378), a TSLP-targeting monoclonal antibody ...
Antibiotic demand for pneumonia and COPD in the top 20 countries showed high global consumption. Researchers conducted a ...
The FDA recently approved mepolizumab for treating adults with inadequately controlled COPD and an eosinophilic phenotype, ...
It is becoming increasingly recognized that people with COPD have an elevated risk of serious CV events,1 discussed Hanania ...
Chinese scientists have developed a novel nanotherapy known as biomimetic extracellular vesicle spherical nucleic acids ...
The study followed 351 patients across four Korean hospitals who had received anti-tuberculosis treatment for more than six months. These individuals were monitored over 11 years (132 months) to ...
The University of Texas at Tyler was awarded a $219,000 grant to help fund a professor’s pulmonary fibrosis treatment project ...
Chronic obstructive pulmonary disease (COPD) affects 25 million people in the U.S. and is the fifth leading cause of death ...
In smokers with COPD, LABA+LAMA is more effective than LABA+ICS in preventing exacerbations, regardless of blood eosinophil count.
A Texas researcher received a $219,000 NIH grant to study the potential of a treatment for radiation-induced pulmonary ...
Researchers discover an unusual accumulation of particles in people with the disease; the causes are still unclear.
With patient enrollment now complete, topline results are expected early next year from a Phase 3 trial testing PAH treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results